Viewing Study NCT04616560


Ignite Creation Date: 2025-12-25 @ 2:17 AM
Ignite Modification Date: 2026-06-14 @ 7:32 AM
Study NCT ID: NCT04616560
Status: SUSPENDED
Last Update Posted: 2025-10-31
First Post: 2020-11-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
Sponsor: National Cancer Institute (NCI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Osteosarcoma View
None Recurrent Osteosarcoma View
Keywords: